Despite the limitations, the area of pharmacogenomics involving CCR5Δ32 genotyping is expected to progress in the next years, especially considering the increasing use of CCR5 modulators to treat other diseases not associated with HIV infection. Here, CCR5 is linked to HIV infectious disease.